New treatments for lung fibrosis using FAK inhibitors
Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis
This study is exploring new treatments for idiopathic pulmonary fibrosis (IPF) by targeting a protein that contributes to lung scarring, with the hope of helping patients breathe better and feel healthier.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Faknostics, LLC NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project ID | NIH-11008778 on NIH RePORTER |
What this research studies
This research focuses on developing novel therapies for idiopathic pulmonary fibrosis (IPF), a serious lung condition that leads to progressive scarring of lung tissue. The approach involves targeting a protein called Focal Adhesion Kinase (FAK), which plays a key role in the development of fibrosis by influencing cell behavior and the secretion of fibrotic proteins. By inhibiting FAK, the research aims to reduce fibrosis and improve lung function in affected patients. The study will involve laboratory experiments and potentially clinical trials to assess the effectiveness of these inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or related fibrotic lung disorders.
Not a fit: Patients with other types of lung diseases or those who do not have a diagnosis of fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung fibrosis, improving patient outcomes and quality of life.
How similar studies have performed: While there have been some successes in targeting FAK in other conditions, this specific approach for lung fibrosis is relatively novel and has not been extensively tested.
Where this research is happening
Phoenix, United States
- Faknostics, LLC — Phoenix, United States (Active)
Researchers
- Principal investigator: Marlowe, Timothy a — Faknostics, LLC
- Study coordinator: Marlowe, Timothy a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.